A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
At a glance
- Drugs MEDI 0700 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Amgen
- 19 Apr 2018 Planned End Date changed from 20 Oct 2018 to 19 Jan 2019.
- 19 Apr 2018 Planned primary completion date changed from 20 Oct 2018 to 19 Jan 2019.
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.